Agomab Therapeutics is a clinical-stage biopharmaceutical company (Nasdaq: AGMB) developing novel disease-modifying therapies for fibro-inflammatory diseases, with an initial focus on chronic fibrotic indications of high unmet medical need such as Crohn's disease and idiopathic pulmonary fibrosis. - View it on GitHub